Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in cash
Terns Pharmaceuticals is being acquired by Merck Sharp & Dohme LLC for $53 per share in cash, a deal that would make Terns a wholly-owned Merck subsidiary and delist its stock. The acquisition highlights Terns’ lead oncology asset, TERN-701 for chronic myeloid leukemia, which has shown promising Phase 1/2 trial data. Terns ended 2025 with strong liquidity of $1.02 billion in cash and marketable securities but continues to report net losses, financing operations primarily through equity offerings.